Zobrazeno 1 - 10
of 87
pro vyhledávání: ''
Autor:
Piotr Rutkowski, Paweł Rogala, Magdalena Wiśniewska, Anna M. Czarnecka, Adrianna Gęga-Czarnota, Bożena Cybulska-Stopa, Łukasz Galus, Tomasz Kubiatowski, Paweł Teterycz, Marcin Rajczykowski, Jacek Mackiewicz, Marek Ziobro, Robert Dziura, Rafał Suwiński
Publikováno v:
Melanoma Research. 30:465-471
Despite considerable progress made in the treatment of patients with advanced melanoma, the majority of the patients treated with BRAF and mitogen-activated protein inhibitors (BRAFi and MEKi) experience a disease progression due to acquired resistan
Autor:
Colin R Lindsay, Pier Francesco Ferrucci, Giuseppe Tonini, Dara Stein, Victoria Atkinson, Paola Queirolo, Barbara Merelli, Philippe Legenne, Massimo Aglietta, Klaus Freivogel, Soizick Mesnage, Michele Del Vecchio, Helen Linardou, Bart Neyns, Salvador Martín-Algarra, Lindi Dalland, Vanna Chiarion-Sileni, Michael Millward, Jonathan Cebon, Rebecca A. Hinshelwood, Mike Lau
Publikováno v:
Melanoma Research. 29:527-532
Given the approval of dabrafenib in patients with BRAF-mutant metastatic melanoma, a better understanding of treatment patterns and clinical outcomes with dabrafenib in a clinical setting is warranted. We performed a retrospective chart review of pat
Autor:
Jarrett J. Failing, Anagha Bangalore Kumar, Robert R. McWilliams, Svetomir N. Markovic, Roxana S. Dronca, Matthew S. Block, Ying Li, Jonas Paludo, Lisa A. Kottschade, Yiyi Yan, Jesus Vera Aguilera, Henan Zhang, Haidong Dong
Publikováno v:
Melanoma Research
Supplemental Digital Content is available in the text.
Management of PD-1 blockade resistance in metastatic melanoma (MM) remains challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting. Chemo-immunotherapy (CIT
Management of PD-1 blockade resistance in metastatic melanoma (MM) remains challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting. Chemo-immunotherapy (CIT
Autor:
Christian U. Blank, Johannes V. Van Thienen, Dieta Brandsma, John B. A. G. Haanen, Willem Boogerd, Marnix H Geukes Foppen
Publikováno v:
Melanoma Research. 28:126-133
Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2-6 months after whole-brain radiotherapy. Targeted therapy (TT) is an effective treatment for BRAF-mutated metastatic melanoma. Moreover, recent studies indicate intr
Autor:
Philippe Bertheau, Cécile Pagès, Céleste Lebbé, Nelson Lourenco, Nadim Mourad, Julie Delyon, Matthieu Allez, Clara Allayous, A. Ballon, Barouyr Baroudjian, Pirayeh Eftekhari
Publikováno v:
Melanoma research. 29(5)
Gastrointestinal toxicities of MEK inhibitors in melanoma patients are frequent. In clinical trials, the most common digestive adverse events were nausea, vomiting, and diarrhoea. However, severe toxicities such as colitis and gastrointestinal perfor
Autor:
Alan G. Palestine, Anna G Mackin, Jennifer L. Patnaik, Rene Gonzalez, William A. Robinson, Amanda L Dinsmore, Paula E. Pecen
Publikováno v:
Melanoma research. 29(5)
The aim of this study was to describe inflammatory side effects in patients treated with BRAF and MEK inhibitors at a single tertiary care institution. This was a retrospective chart review of patients prescribed single-agent or combination BRAF and
Autor:
Antonia Dimitrakopoulou-Strauss, Annette Kopp-Schneider, Lara Elena Hakim-Meibodi, Christos Sachpekidis, Jessica C. Hassel
Publikováno v:
Melanoma research. 29(2)
Sixteen BRAF-mutation positive, metastatic melanoma patients with highly advanced disease received combination therapy of vemurafenib and ipilimumab as an individual treatment decision. Our aim was to assess the role of fluorine-18-fluorodeoxyglucose
Publikováno v:
Melanoma research. 28(5)
A history of melanoma within the preceding 5 years is commonly considered a contraindication to solid organ transplantation. We investigated how a pretransplant history of melanoma impacts patient survival and melanoma recurrence. Institutional Revie
Autor:
Samy Ammari, Salima Hibat-Allah, Frédéric Dhermain, Mathieu Texier, Charlée Nardin, Caroline Robert, Christine Mateus, Emilie Lanoy
Publikováno v:
Melanoma research. 28(2)
Anti-programmed cell death-1 (anti-PD1) antibodies are currently the first-line treatment for patients with metastatic BRAF wild-type melanoma, alone or combined with the anti-CTLA4 monoclonal antibody, ipilimumab. To date, data on safety and the out
Autor:
Eleni Iordanou, Ulrike Leiter, Martin Röcken, Claus Garbe, Andrea Forschner, Friedegund Meier, Christina Schraml, Benjamin Weide, Daniel Zips
Publikováno v:
Melanoma Research. 24:512-516
The basis of radiation recall reactions (RRR) is a subclinical radiation damage that is uncovered later by treatment with anticancer agents. Several drugs have been associated with RRR, in particular taxanes and anthracyclines. Recently, a few cases